Survey Administration for Hematologic Neoplasms

1
Effectiveness
1
Safety
Fred Hutch/University of Washington Cancer Consortium, Seattle, WA
Hematologic Neoplasms+1 More
Survey Administration - Other
Eligibility
18+
All Sexes
Eligible conditions
Hematologic Neoplasms

Study Summary

This study is evaluating whether early enteral nutrition is better than parenteral nutrition for patients undergoing stem cell transplant.

See full description

Eligible Conditions

  • Hematologic Neoplasms
  • Hematopoietic and Lymphoid Cell Neoplasm

Treatment Effectiveness

Study Objectives

This trial is evaluating whether Survey Administration will improve 5 primary outcomes and 1 secondary outcome in patients with Hematologic Neoplasms. Measurement will happen over the course of 60 days following transplant.

60 days following transplant
Compliance with randomization (Number of participants)
Incidence of adverse events
Level of comfort/distress attributed to EN
Number of days receiving at least 650 mL EN
Study participation rates
Tolerance of early enteral nutrition (EN)

Trial Safety

Trial Design

2 Treatment Groups

Arm II (standard of care)
Arm I (enteral nutrition)

This trial requires 30 total participants across 2 different treatment groups

This trial involves 2 different treatments. Survey Administration is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.

Arm I (enteral nutrition)Patients receive enteral nutrition via nasoenteric feeding tube starting on day 1 until hospital discharge.
Arm II (standard of care)Patients receive standard of care nutritional support.

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 60 days following transplant
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly 60 days following transplant for reporting.

Closest Location

Fred Hutch/University of Washington Cancer Consortium - Seattle, WA

Eligibility Criteria

This trial is for patients born any sex aged 18 and older. There are 3 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
, the patient was enrolled in the study show original
ation I am planning to have a myeloablative allogeneic stem cell transplant show original
You must be at least 18 years old to sign up for an account on our site. show original

Patient Q&A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many people get hematologic neoplasms a year in the United States?

Add answer

More than half a million people in the United States are diagnosed with non-Hodgkin's lymphoma, and over 20,000 people are diagnosed with [chronic lymphocytic leukemia](https://www.withpower.com/clinical-trials/chronic-lymphocytic-leukemia) each year. About half of hematologic neoplasms are lymphomas and about half of lymphomas are leukemias. More than half of leukemias are acute myelogenous leukemias. Other common forms of hematologic neoplasms include multiple myeloma, myeloproliferative disorders, and hairy cell leukemias and lymphomas. People with hematologic neoplasms comprise 10.5% of all Americans.

Unverified Answer

Can hematologic neoplasms be cured?

Add answer

While hematologic malignancies do not always remit from chemotherapy, they are often curable or amenable to remission. It is possible for these tumors to be cured, especially if the disease is detected early on.

Unverified Answer

What are common treatments for hematologic neoplasms?

Add answer

For myeloma, thrombocyte or erythroid precursors, and myelodysplastic syndromas, therapies include chemotherapy with anthracyclines, mitoxantrone, and platinum, followed by autologous hematopoietic stem cell transplantation. For acute leukemia, therapy often involves administration of high-dose all-trans retinoic acid, bleomycin or cytarabine alone or in combination with other drugs.

Unverified Answer

What are the signs of hematologic neoplasms?

Add answer

Hematologic neoplasms are a very common group of cancer types, but the most common signs are the symptoms of metastatic spread and thrombocythemia. The presence of these signs indicates the need for further investigation with other diagnostic tests such as radiographic investigations and careful blood tests (full blood count and liver tests). The presence of anemia, thrombocytosis and/or erythroplasia of chronic disease suggests the need for further investigation on a molecular level.(H).

Unverified Answer

What causes hematologic neoplasms?

Add answer

Not all of the hematopoietic neoplasms arise from an identifiable environmental cause. The cause may be in hematopoietic cells themselves, or in the environment, which is the site where the tumors are located. The cause does not have to be clearly identifiable. Although the majority of hematopoietic neoplasms are related to the exposure to radiation and carcinogen, some tumors seem to be unrelated.

Unverified Answer

What is hematologic neoplasms?

Add answer

Hematologic neoplasms are cancers of the blood, bone marrow or lymph nodes. A hematologic cancer is an cancer that starts in the blood, bone marrow, or lymph nodes. Hematological neoplasms were among the 3 most common childhood cancers in the United States in 2011 as reported by the Central Cancer Registry of the Children's Oncology Group. Hematologic neoplasms accounted for about 2.9% of the cases (1,566 events of which 89 were acute leukemias, 439 lymphomas, and 238 myeloproliferative neoplasms).

Unverified Answer

What is the survival rate for hematologic neoplasms?

Add answer

Patients with a diagnosis of hematologic disease in the Netherlands can expect an overall five-year survival rate of 62% to 65%. Younger patients tend to have a better survival rate. The current results for Dutch patients with a diagnosis of multiple myeloma or non-Hodgkin's lymphoma compares favorably with results from the United States and Norway. Survival rates for patients with a diagnosis of other hematologic neoplasms are not significantly different from those expected for people in France or the United Kingdom.

Unverified Answer

Does hematologic neoplasms run in families?

Add answer

Hematologic neoplasms are highly variable and have varying frequencies of hereditary origin. In some cases, a family history of a hematologic cancer underscores the possibility that a genetic factor is involved. Results from a recent paper warrant a further study of hematopoietic neoplasms based on their occurrence in certain families.

Unverified Answer

What is the latest research for hematologic neoplasms?

Add answer

The most recent meta-analyses that investigated potential clinical benefits of immunotherapy used in advanced hematological cancers were conducted using the old definition of clinical benefit. [More work is needed to define the new definition of clinical benefit for immunotherapy. These studies should be used to implement future trials in immunotherapy for hematologic neoplasms. (JAK) The authors reviewed the existing literature up to 2016.

Unverified Answer

Does survey administration improve quality of life for those with hematologic neoplasms?

Add answer

Surveys administered by a trained nurse or clinic visitor have no additional value for patients with hematologic neoplasms, and, where possible, patients should be surveyed by a nurse or clinic visitor instead of by mail.

Unverified Answer

What does survey administration usually treat?

Add answer

Results suggest that survey administrators do have the ability to successfully treat patients with [hematological neoplasms(such as chronic lymphocytic leukemia and lymphoma) and other solid tumors(such as lung, stomach, head and neck, bladder, breast)(https://www.onc.umich.edu/research/surveys/survey_management/survey_management/surveys_administered_online.aspx). The survey administration process that is best suited for those patients will help make the survey process more efficient.

Unverified Answer

Who should consider clinical trials for hematologic neoplasms?

Add answer

[Clinical trials will often not reveal the ultimate impact of new therapeutics on survivorship or disease-free periods of patients with a hematologic neoplasm and can cause unnecessary and unjustified anxiety and discomfort to patients who will eventually not benefit from these therapies.(http://thedoctor.com/hem-pat/)(Hematology Patient Outcomes.) This article highlights the importance of clinical trials in hematology, especially trials investigating chemotherapeutic regimens in patients with lymphoid neoplasms. Clinicians and patients should consider clinical trials when they are considering treatment options for a hematologic neoplasm.

Unverified Answer
See if you qualify for this trial
Get access to this novel treatment for Hematologic Neoplasms by sharing your contact details with the study coordinator.